Compare Stocks: PLX, DRUG, CADL, and RIGL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$11.72 -0.7%	$9.68	$4.35 ▼ $11.95	$864.59M	-0.51	1.18 million shs	2.07 million shs
DRUG Bright Minds Biosciences	$76.44 -2.0%	$70.69	$38.00 ▼ $123.75	$759.11M	-5.27	191,720 shs	151,386 shs
PLX Protalix BioTherapeutics	$2.22 -5.9%	$2.29	$1.46 ▼ $3.19	$178.87M	0.02	948,827 shs	995,501 shs
RIGL Rigel Pharmaceuticals	$42.58 +4.4%	$38.04	$24.95 ▼ $52.24	$754.70M	1.16	315,481 shs	224,018 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	+10.49%	+11.53%	+19.55%	+34.55%	+84.38%
DRUG Bright Minds Biosciences	-1.73%	-3.47%	+5.36%	+0.68%	+92.40%
PLX Protalix BioTherapeutics	-9.92%	-3.28%	+2.16%	+19.19%	+46.58%
RIGL Rigel Pharmaceuticals	-2.58%	+4.00%	-0.92%	+40.61%	+11.51%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$11.72 -0.7%	$9.68	$4.35 ▼ $11.95	$864.59M	-0.51	1.18 million shs	2.07 million shs
DRUG Bright Minds Biosciences	$76.44 -2.0%	$70.69	$38.00 ▼ $123.75	$759.11M	-5.27	191,720 shs	151,386 shs
PLX Protalix BioTherapeutics	$2.22 -5.9%	$2.29	$1.46 ▼ $3.19	$178.87M	0.02	948,827 shs	995,501 shs
RIGL Rigel Pharmaceuticals	$42.58 +4.4%	$38.04	$24.95 ▼ $52.24	$754.70M	1.16	315,481 shs	224,018 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	+10.49%	+11.53%	+19.55%	+34.55%	+84.38%
DRUG Bright Minds Biosciences	-1.73%	-3.47%	+5.36%	+0.68%	+92.40%
PLX Protalix BioTherapeutics	-9.92%	-3.28%	+2.16%	+19.19%	+46.58%
RIGL Rigel Pharmaceuticals	-2.58%	+4.00%	-0.92%	+40.61%	+11.51%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	2.60	Moderate Buy	$19.29	64.55% Upside
DRUG Bright Minds Biosciences	3.14	Buy	$143.83	88.17% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$12.00	440.54% Upside
RIGL Rigel Pharmaceuticals	2.50	Moderate Buy	$61.50	44.43% Upside

Current Analyst Ratings Breakdown

Latest PLX, DRUG, CADL, and RIGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	RIGL Rigel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$57.00 ➝ $85.00
8/14/2026	CADL Candel Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$9.00 ➝ $12.00
8/13/2026	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$23.00
8/6/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/6/2026	RIGL Rigel Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/29/2026	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$23.00
7/21/2026	DRUG Bright Minds Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/17/2026	CADL Candel Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
7/13/2026	CADL Candel Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$22.00
6/2/2026	RIGL Rigel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$57.00

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	$0.95 per share	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$8.33 per share	N/A
PLX Protalix BioTherapeutics	$76.38M	2.34	$0.12 per share	17.80	$0.47 per share	4.72
RIGL Rigel Pharmaceuticals	$294.28M	2.68	$7.04 per share	6.05	$22.99 per share	1.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	-$38.18M	-$0.98	N/A	N/A	N/A	N/A	-84.70%	-54.37%	N/A
DRUG Bright Minds Biosciences	-$8.74M	-$2.44	N/A	N/A	N/A	N/A	-20.58%	-20.25%	N/A
PLX Protalix BioTherapeutics	$8.31M	$0.18	N/A	7.16	N/A	-21.03%	-30.89%	-11.74%	N/A
RIGL Rigel Pharmaceuticals	$367.02M	$16.32	2.61	11.70	N/A	116.30%	22.95%	17.19%	N/A

Latest PLX, DRUG, CADL, and RIGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q3 2026	DRUG Bright Minds Biosciences	-$1.2831	-$0.17	+$1.1131	-$0.17	N/A	N/A
8/13/2026	Q2 2026	CADL Candel Therapeutics	-$0.2738	-$0.52	-$0.2462	-$0.52	N/A	N/A
8/4/2026	Q2 2026	RIGL Rigel Pharmaceuticals	$0.0877	$0.88	+$0.7923	$0.88	$55.28 million	$78.70 million
5/20/2026	Q2 2026	DRUG Bright Minds Biosciences	-$0.8633	-$0.80	+$0.0633	-$0.80	N/A	N/A
5/14/2026	Q1 2026	CADL Candel Therapeutics	-$0.2958	-$0.14	+$0.1558	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CADL Candel Therapeutics	0.34	28.05	28.05
DRUG Bright Minds Biosciences	N/A	81.47	81.47
PLX Protalix BioTherapeutics	N/A	1.98	1.27
RIGL Rigel Pharmaceuticals	N/A	1.94	1.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
DRUG Bright Minds Biosciences	40.52%
PLX Protalix BioTherapeutics	16.53%
RIGL Rigel Pharmaceuticals	66.23%

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	14.30%
DRUG Bright Minds Biosciences	42.66%
PLX Protalix BioTherapeutics	6.70%
RIGL Rigel Pharmaceuticals	10.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	60	73.27 million	62.79 million	Optionable
DRUG Bright Minds Biosciences	N/A	9.73 million	5.58 million	Not Optionable
PLX Protalix BioTherapeutics	200	80.57 million	69.00 million	Optionable
RIGL Rigel Pharmaceuticals	160	18.50 million	16.57 million	Optionable

PLX, DRUG, CADL, and RIGL Headlines

Recent News About These Companies

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

August 13 at 8:05 AM | prnewswire.com

Rigel Pharmaceuticals, Inc. $RIGL Shares Purchased by Dimensional Fund Advisors LP

August 10, 2026 | marketbeat.com

HC Wainwright Brokers Reduce Earnings Estimates for RIGL

August 9, 2026 | americanbankingnews.com

Janus Henderson Group PLC Boosts Position in Rigel Pharmaceuticals, Inc. $RIGL

August 8, 2026 | marketbeat.com

HC Wainwright Issues Pessimistic Outlook for RIGL Earnings

August 8, 2026 | americanbankingnews.com

HC Wainwright Issues Pessimistic Estimate for RIGL Earnings

August 7, 2026 | marketbeat.com

Pacer Advisors Inc. Purchases 48,882 Shares of Rigel Pharmaceuticals, Inc. $RIGL

August 7, 2026 | marketbeat.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap Up After Better-Than-Expected Earnings

August 7, 2026 | americanbankingnews.com

HC Wainwright Issues Pessimistic Forecast for RIGL Earnings

August 6, 2026 | marketbeat.com

Empowered Funds LLC Takes Position in Rigel Pharmaceuticals, Inc. $RIGL

August 6, 2026 | marketbeat.com

Rigel Pharmaceuticals en quête d'acquisitions

August 5, 2026 | zonebourse.comZ

Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

August 5, 2026 | seekingalpha.com

Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)

August 5, 2026 | seekingalpha.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap Up on Earnings Beat

August 5, 2026 | marketbeat.com

Rigel: Q2 Earnings Snapshot

August 4, 2026 | aol.comA

Rigel Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 4, 2026 | seekingalpha.com

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript

August 4, 2026 | seekingalpha.com

Rigel Pharmaceuticals Q2 Earnings Call Highlights

August 4, 2026 | marketbeat.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Posts Earnings Results, Beats Estimates By $0.79 EPS

August 4, 2026 | marketbeat.com

Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates

August 4, 2026 | zacks.com

Rigel Reports Second Quarter 2026 Financial Results

August 4, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PLX, DRUG, CADL, and RIGL Company Descriptions

Candel Therapeutics NASDAQ:CADL

$11.72 -0.08 (-0.68%)

Closing price 04:00 PM Eastern

Extended Trading

$11.65 -0.07 (-0.60%)

As of 07:34 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Bright Minds Biosciences NASDAQ:DRUG

$76.44 -1.56 (-2.00%)

Closing price 04:00 PM Eastern

Extended Trading

$76.25 -0.19 (-0.25%)

As of 07:34 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Protalix BioTherapeutics NYSE:PLX

$2.22 -0.14 (-5.93%)

Closing price 04:00 PM Eastern

Extended Trading

$2.25 +0.03 (+1.17%)

As of 07:57 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Rigel Pharmaceuticals NASDAQ:RIGL

$42.58 +1.79 (+4.39%)

Closing price 04:00 PM Eastern

Extended Trading

$42.67 +0.09 (+0.21%)

As of 07:37 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PLX, DRUG, CADL, and RIGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PLX, DRUG, CADL, and RIGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PLX, DRUG, CADL, and RIGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PLX, DRUG, CADL, and RIGL Company Descriptions

Candel Therapeutics NASDAQ:CADL

Bright Minds Biosciences NASDAQ:DRUG

Protalix BioTherapeutics NYSE:PLX

Rigel Pharmaceuticals NASDAQ:RIGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PLX, DRUG, CADL, and RIGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PLX, DRUG, CADL, and RIGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PLX, DRUG, CADL, and RIGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PLX, DRUG, CADL, and RIGL Company Descriptions

Candel Therapeutics NASDAQ:CADL

Bright Minds Biosciences NASDAQ:DRUG

Protalix BioTherapeutics NYSE:PLX

Rigel Pharmaceuticals NASDAQ:RIGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools